Aller au contenu

BiotechTV - News

BiotechTV
BiotechTV - News
Dernier épisode

484 épisodes

  • BiotechTV - News

    Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease

    02/10/2026 | 20 min
    CEO Markus Warmuth walks us through the data and provides a broader update on the pipeline progress at Monte Rosa and for the field of degraders and molecular glues more broadly.
  • BiotechTV - News

    From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung

    29/09/2026 | 7 min
    CEO Stefanie Fluckiger-Mangual describes the rationale for targeting CPB/p300 and walks us through TOLREMO's recently presented phase 1 data, which had a clean safety profile and showed evidence of anti-tumor activity.
  • BiotechTV - News

    From Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage

    28/09/2026 | 9 min
    Co-Founder & Partner Sascha Oliver Bucher describes the firm and investments it has been making, and shares his thoughts on the VC ecosystem in Europe.
  • BiotechTV - News

    From Basel: With two products on the market with momentum and a key pipeline asset in a P3, Basilea has become a world leader in the development of therapies for bacterial and fungal infections

    28/09/2026 | 13 min
    CEO David Veitch discusses Cresemba and Zevtera, both of which have momentum in what used to be market with structural barriers to commercial success, but no longer are in most geographies. Plus, a key phase 3 that will read out for Basilea's next mold infection program, fosmanogepix, in 2028.
  • BiotechTV - News

    Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa succeeded on its primary endpoint of helping patients to see better on low luminance visual acuity in a phase three study

    21/09/2026 | 9 min
    Chris Hollowood, Founder of Beacon and CEO of Syncona, describes the top line result and its significance. This is the first pivotal trial in X-linked retinitis pigmentosa to achieve its primary endpoint.
Plus de podcasts Science de la vie
À propos de BiotechTV - News
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Site web du podcast

Écoutez BiotechTV - News, The Joy of Why ou d'autres podcasts du monde entier - avec l'app de radio.fr

Obtenez l’app radio.fr
 gratuite

  • Ajout de radios et podcasts en favoris
  • Diffusion via Wi-Fi ou Bluetooth
  • Carplay & Android Auto compatibles
  • Et encore plus de fonctionnalités
BiotechTV - News: Podcasts du groupe
Applications
Réseaux sociaux
v8.21.0 | © 2007-2026 radio.de GmbH
Generated: 10/3/2026 - 9:51:58 AM